Pharmaceuticals, Inc. PPHMAdd to PortfolioGet E-mail AlertsPrint This PagePDF ReportData QuestionQuoteChartStock AnalysisPerformanceKey RatiosFinancialsValuationInsidersShareholdersTranscripts newFilingsBondsOptionOverviewExecutive CompensationInsider ActivityKey ExecutivesBoard of DirectorsCommittees
2013 Executive Compensation Compensation vs. Performance (1-Year % Change)
Total Compensation 1-Year % Change CEO Compensation Stock Return Revenue Return on Equity Net Income
$4,409,039 18.93 % -1.37% 28.16% 40.00% 47.04% 30.95%
Total Executive Compensation PPHM200920102011201220132 mil4 mil6 mil1.53 mil2.83 mil1.61 mil3.71 mil4.41 milStock Price Stock PriceTotal ReturnRevenueReturn of EquityNet Income
Note: Currency in USD.
See Salary, Bonus, and Pay details for Jobs at PPHM
Key Executive Compensation PPHM Name/Title 2009 2010 2011 2012 2013
Key Executive Compensation 1,264,361 2,825,165 1,612,549 3,707,196 4,409,039
Salary 1,206,511 1,215,878 1,210,562 1,553,643 1,894,308
Bonus 0 264,274 163,076 148,500 0
Annual Other Income 0 0 0 0 0
Restricted Stock Award 0 96,690 78,210 0 0
Securities Options 0 948,022 0 1,087,363 1,397,693
LTIP Payout 0 0 0 0 0
Non-Equity Compensation 0 151,521 0 622,400 865,742
Other Compensation 57,850 148,780 160,701 295,290 251,296
Total 1,264,361 2,825,165 1,612,549 3,707,196 4,409,039
Steven W. King/President and Chief Executive Officer 426,846 1,124,425 542,198 1,160,553 1,144,645
Salary 407,557 403,755 390,009 428,250 445,830
Bonus 0 97,502 62,401 0 0
Annual Other Income 0 0 0 0 0
Restricted Stock Award 0 41,020 33,180 0 0
Securities Options 0 426,706 0 441,119 349,410
LTIP Payout 0 0 0 0 0
Non-Equity Compensation 0 99,939 0 257,400 313,706
Other Compensation 19,289 55,503 56,608 33,784 35,699
Total 426,846 1,124,425 542,198 1,160,553 1,144,645
Paul J. Lytle/Chief Financial Officer 337,487 729,101 418,478 666,729 790,754
Salary 318,198 315,229 304,497 325,402 338,593
Bonus 0 60,899 45,675 0 0
Annual Other Income 0 0 0 0 0
Restricted Stock Award 0 26,370 21,330 0 0
Securities Options 0 231,696 0 177,243 257,880
LTIP Payout 0 0 0 0 0
Non-Equity Compensation 0 51,582 0 130,300 158,833
Other Compensation 19,289 43,325 46,976 33,784 35,448
Total 337,487 729,101 418,478 666,729 790,754
Jeffrey L. Masten/Vice President, Quality - - - 831,688 684,892
Salary - - - 259,789 296,181
Bonus - - - 142,500 0
Annual Other Income - - - 0 0
Restricted Stock Award - - - 0 0
Securities Options - - - 252,235 193,410
LTIP Payout - - - 0 0
Non-Equity Compensation - - - 0 97,256
Other Compensation - - - 177,164 98,045
Total - - - 831,688 684,892
Mark R. Ziebell/Vice President, General Counsel and Corporate Secretary - - - - 610,255
Salary - - - - 252,000
Bonus - - - - 0
Annual Other Income - - - - 0
Restricted Stock Award - - - - 0
Securities Options - - - - 217,800
LTIP Payout - - - - 0
Non-Equity Compensation - - - - 111,501
Other Compensation - - - - 28,954
Total - - - - 610,255
Shelley P.m. Fussey/Vice President, Intellectual Property 275,962 516,418 335,539 478,518 590,492
Salary 275,962 285,577 275,000 280,394 291,504
Bonus 0 55,000 27,500 0 0
Annual Other Income 0 0 0 0 0
Restricted Stock Award 0 14,650 11,850 0 0
Securities Options 0 144,810 0 83,254 185,783
LTIP Payout 0 0 0 0 0
Non-Equity Compensation 0 0 0 98,200 95,721
Other Compensation 0 16,381 21,189 16,670 17,484
Total 275,962 516,418 335,539 478,518 590,492
Joseph S. Shan/Vice President, Clinical and Regulatory Affairs 224,066 455,221 316,334 569,708 588,001
Salary 204,794 211,317 241,056 259,808 270,200
Bonus 0 50,873 27,500 6,000 0
Annual Other Income 0 0 0 0 0
Restricted Stock Award 0 14,650 11,850 0 0
Securities Options 0 144,810 0 133,512 193,410
LTIP Payout 0 0 0 0 0
Non-Equity Compensation 0 0 0 136,500 88,725
Other Compensation 19,272 33,571 35,928 33,888 35,666
Total 224,066 455,221 316,334 569,708 588,001
A publicly-traded company is only required to disclose information concerning the amount and type of compensation paid to its CEO, CFO, and the three other most highly compensated executive officers in a given year. Information about compensation for these individuals may be unavailable in prior years if they were not in their current roles or did not qualify as among the most highly compensated officers at the time. We value your feedback. Let us know what you think.
